These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 34906030)
21. Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims. Zhu C; Zaidman C; Youn B; Paradis AD; Raynaud S; Neville BA; Johnson NB J Comp Eff Res; 2024 Jul; 13(7):e230187. PubMed ID: 38963060 [No Abstract] [Full Text] [Related]
22. Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy. Tan H; Gu T; Chen E; Punekar R; Shieh PB J Health Econ Outcomes Res; 2019; 6(3):185-195. PubMed ID: 37362080 [No Abstract] [Full Text] [Related]
23. Healthcare Utilization, Costs of Care, and Mortality Among Psatients With Spinal Muscular Atrophy. Tan H; Gu T; Chen E; Punekar R; Shieh PB J Health Econ Outcomes Res; 2019; 6(3):185-195. PubMed ID: 32685590 [TBL] [Abstract][Full Text] [Related]
24. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144 [TBL] [Abstract][Full Text] [Related]
26. Spinal motor neuron loss occurs through a p53-and-p21-independent mechanism in the Smn Reedich EJ; Kalski M; Armijo N; Cox GA; DiDonato CJ Exp Neurol; 2021 Mar; 337():113587. PubMed ID: 33382987 [TBL] [Abstract][Full Text] [Related]
27. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020 [TBL] [Abstract][Full Text] [Related]
28. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. Farrar MA; Carey KA; Paguinto SG; Chambers G; Kasparian NA BMJ Open; 2018 May; 8(5):e020907. PubMed ID: 29794098 [TBL] [Abstract][Full Text] [Related]
29. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Vuillerot C; Payan C; Iwaz J; Ecochard R; Bérard C; Arch Phys Med Rehabil; 2013 Aug; 94(8):1555-61. PubMed ID: 23380348 [TBL] [Abstract][Full Text] [Related]
30. High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1): Retrospective Analysis of the Kids' Inpatient Database (KID). Cardenas J; Menier M; Heitzer MD; Sproule DM Pharmacoecon Open; 2019 Jun; 3(2):205-213. PubMed ID: 30182345 [TBL] [Abstract][Full Text] [Related]
31. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis. Darbà J; Marsà A BMJ Open; 2019 Nov; 9(11):e031271. PubMed ID: 31753879 [TBL] [Abstract][Full Text] [Related]
33. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328 [TBL] [Abstract][Full Text] [Related]
34. Correlation between deletion patterns of SMN and NAIP genes and the clinical features of spinal muscular atrophy in Indian patients. Dastur RS; Gaitonde PS; Khadilkar SV; Udani VP; Nadkarni JJ Neurol India; 2006 Sep; 54(3):255-9. PubMed ID: 16936383 [TBL] [Abstract][Full Text] [Related]
35. Epidemiology and healthcare utilization of First Nations peoples living with spinal cord injury in Alberta: an observational study to explore health inequities. Wegenast BF; Whitten TA; Bakal JA; Bill L; Loyola-Sanchez A Spinal Cord Ser Cases; 2023 Sep; 9(1):48. PubMed ID: 37679339 [TBL] [Abstract][Full Text] [Related]
36. Spinal muscular atrophy: survival pattern and functional status. Chung BH; Wong VC; Ip P Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357 [TBL] [Abstract][Full Text] [Related]
37. Nusinersen: A Review in 5q Spinal Muscular Atrophy. Hoy SM CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360 [TBL] [Abstract][Full Text] [Related]
38. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States. Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864 [TBL] [Abstract][Full Text] [Related]
39. A Study on the Incidence and Prevalence of 5q Spinal Muscular Atrophy in Canada Using Multiple Data Sources. Price TR; Hodgkinson V; Westbury G; Korngut L; Innes MA; Marshall CR; Nelson TN; Huang L; Parboosingh J; Mah JK Can J Neurol Sci; 2024 Jan; ():1-12. PubMed ID: 38178730 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K; Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]